XTLB vs MCVT Comparison

XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.